Bacteriophage therapy

 Bacteriophage therapy: where are we now?

13 June at 13.30 CET

Join us for an insightful webinar exploring two critical frontiers in the advancement of bacteriophage-based treatments: "Phage Pharmacokinetics: Why Does It Matter?" and "Phage Therapy: Building a Bridge Between Researchers and Clinicians." Discover why the absorption, distribution and elimination of phages is a central problem in using phages clinically. Then, dive into the collaborative challenges and opportunities in translating laboratory breakthroughs into bedside applications. This session brings together two leading experts to share the latest research, clinical perspectives, and practical strategies for fostering interdisciplinary dialogue and accelerating the clinical adoption of phage therapy. Whether you're a researcher, clinician, or industry professional, this is your chance to stay at the forefront of a rapidly evolving field.

Krystyna Dąbrowska (Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Poland)

Krystyna Dąbrowska is a molecular biologist and full professor (from the year 2022), affiliated to Institute of Immunology and Experimental Therapy, Polish Academy of Sciences (from the year 2000), Regional Specialist Hospital, Research and Development Center (from the year 2016), and to Wrocław University of Science and Technology (from the year 2023).

Dr Dabrowski's major fields of research are immune response to bacteriophage as it relates to phage therapy trials; phage pharmacokinetics and phage effects on mammalian systems and cells; molecular determinants of bacteriophage interaction with immune system elements, phage pharmacokinetics and pharmacodynamics, safety, and phage antibacterial potential in animals and humans.

Dr Aycan Gundogdu (Erciyes University School of Medicine, Türkiye / Genome and Stem Cell Center, Türkiye)

Dr Aycan Gundogdu earned her Ph.D. in Medical Microbiology from the University of the Sunshine Coast, Australia, and later served as a postdoctoral researcher. She was actively involved in metagenomics, microbiome, and bacteriophage projects at renowned institutions like the University of the Sunshine Coast, Queensland Health Department, The Commonwealth Scientific and Industrial Research Organisation (CSIRO), Eliava Institute, and the Federal Institute for Risk Assessment (BfR). After returning to Turkey in 2015, she played a key role in founding the Metagenomics Division at Erciyes University’s Genome and Stem Cell Center. As a principal investigator, she managed several national and international projects. She dedicated a portion of her academic journey to bacteriophage research at the Eliava Institute in Georgia in 2016, and subsequently, at the BfR in Berlin, Germany, between 2023-2024. She is a co-founder of Enbiosis Biotechnology, which was founded as a spin-off enterprise from her laboratory in 2019, where she currently serves as the Chief Scientific Officer. Her significant contributions earned her a spot on the Turkish Scientific and Technological Research Council (TUBITAK) – Health Sciences Research Support Group (SBAG) Advisory Board in 2019. Subsequently, in 2021, she was further appointed as a member of the General Executive Board of TUBITAK. Her team’s research primarily delved into discovering biomarkers from disease microbiomes, manipulating microbiomes, studying viromes, constructing bacteriophage libraries and implementing phage therapies. Her collection of intellectual properties includes various patents, mainly focusing on disease diagnosis using microbial biomarkers and crafting biotherapeutics.

ISAC disclaimer